In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Pocket Guidelines on Cardiomyopathies

ESC Pocket Guidelines

Cardiovascular Surgery
Myocardial Disease
Congenital Heart Disease and Pediatric Cardiology
Device Therapy
Interventional Cardiology
Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
Chronic Heart Failure

Publication Date: 2023

Chairpersons: Elena Arbelo and Juan Carlo Kaski

Order Pocket Guidelines

Table of Contents

1. Introduction

2. Phenotypic approach to cardiomyopathies

2.1. Definitions

2.2. Cardiomyopathy phenotypes

2.2.1. Hypertrophic cardiomyopathy

2.2.2. Dilated cardiomyopathy

2.2.3. Non-dilated left ventricular cardiomyopathy

2.2.4. Arrhythmogenic right ventricular cardiomyopathy

2.2.5. Restrictive cardiomyopathy

3. Integrated patient management

4. The patient pathway

4.1. Clinical presentation and initial work-up

4.2. Resting and ambulatory electrocardiography

4.3. Laboratory tests

4.4. Multimodality imaging

4.4.1. General considerations

4.4.2. Echocardiography

4.4.3. Cardiac magnetic resonance

4.4.4. Computed tomography and nuclear medicine techniques

4.4.5. Endomyocardial biopsy

4.5. Genetic testing and counselling

4.5.1. Genetic testing

4.5.2. Genetic counselling

4.6. Diagnostic approach to paediatric patients

4.7. General management principles

4.7.1. Assessment of symptoms

4.7.2. Cardiac transplantation

4.7.3. Left ventricular assist devices

4.7.4. Management of atrial arrhythmias

4.7.5. Device therapy: implantable cardioverter defibrillator

4.7.6. Routine follow-up of patients with cardiomyopathy

4.8. Family screening and follow-up evaluation of relatives

4.9. Psychological support in cardiomyopathy patients and family members

5. Specific cardiomyopathy phenotypes

5.1. Hypertrophic cardiomyopathy

5.1.1. Echocardiography

5.1.2. Cardiac magnetic resonance

5.1.3. Management of symptoms and complications

5.1.4. Drug therapy

5.1.5. Invasive treatment of left ventricular outflow tract

5.1.6. Heart failure and chest pain

5.1.7. Sudden cardiac death prevention

5.2. Dilated cardiomyopathy

5.2.1. Sudden cardiac death prevention in dilated cardiomyopathy

5.3. Non-dilated left ventricular cardiomyopathy

5.3.1. Diagnosis

5.3.2. Sudden cardiac death prevention

5.4. Arrhythmogenic right ventricular cardiomyopathy

5.4.1. Diagnosis

5.4.2. Management

5.4.3. Sudden cardiac death prevention

5.5. Restrictive cardiomyopathy

5.5.1. Management

5.6. Syndromic and metabolic cardiomyopathies

5.6.1. Anderson–Fabry disease

5.7. Amyloidosis

6. Other recommendations

6.1. Exercise recommendations in dilated cardiomyopathy and NDLVC

6.2. Peripartum cardiomyopathy

6.3. Recommendations for non-cardiac surgery

7. Living with cardiomyopathy: advice for patients

8. Comorbidities and cardiovascular risk factors in cardiomyopathies